https://www.selleckchem.com/pr....oducts/Gefitinib.htm
The higher BRAF and fewer TP53 mutations may be related to the lower malignancy in MPLC patients. The accuracy of pathological diagnosis in patients with early-stage MPLC does not need comprehensive molecular evaluation to supplement histology for differentiating early-stage MPLC and IM. Meanwhile, the molecular difference between MPLC and IPLC may be helpful to study the mechanism of MPLC pathogenesis. The accuracy of pathological diagnosis in patients with early-stage MPLC does not need comprehensive molecular evaluation to suppleme
Like
Comment
Share
